Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (alloHCT) and subsequently relapsed.
Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.
A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.
With the help of Marker’s technology, a population of T-cells attacks multiple cancer targets and works to activate a patient’s immune system to trigger anti-tumor activity.
DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.
The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.
Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).
The Department of Defense awarded more than $11 million for this Jacksonville study.